IntrinsicIntrinsic
← All summaries

BrightSpring Health Services, Inc.

BTSG
Financials & Chart →

Business Summary

BrightSpring Health Services, Inc. (the "Company") operates as a leading home and community-based healthcare services platform, focusing on delivering complementary pharmacy and provider services to complex patients. The Company's integrated model addresses critical services for high-need and high-cost Senior and Specialty patients, including Behavioral populations, primarily in lower-cost home and community settings. This market is estimated to be over $2.0 trillion across the Company's business, with chronic conditions driving a disproportionate share of future healthcare expenditures. The Company serves over 465,000 patients daily through approximately 10,500 clinical providers and pharmacists , with a presence across all 50 states .

The Company's core business model revolves around generating revenue from two primary segments: Pharmacy Solutions and Provider Services. Revenue is primarily derived from federal, state, and local government programs such as Medicare (Parts A, B, C, and D) and Medicaid, as well as commercial insurance, Pharmacy Benefit Managers (PBMs), and private pay consumers. The business model emphasizes high-touch and coordinated services, aiming to improve quality and patient experiences while reducing overall costs by providing care in non-institutional home and community settings. The Company's platform is designed to develop longitudinal relationships with patients, managing daily medication requirements, providing primary care and skilled nursing services, and addressing social determinants of health.

The Pharmacy Solutions segment provides daily medication therapy management to various customer and patient types wherever they reside in the community. This includes home and in-clinic infusion patients, oncology and other specialty patients in their homes, residents of independent and senior living communities, hospice patients, neuro clients, residents of skilled nursing and rehabilitation facilities, hospital patients, and Seniors on multiple medications. In 2025, this segment filled over 43 million prescriptions from over 175 pharmacies across all 50 states , serving approximately 6,600 customer locations , approximately 73,000 individual or group homes , and over 410,000 patients through more than 4,500 unique customer and payor contracts . Revenue for Pharmacy Solutions was $11,445.8 million in 2025, representing 88.7% of total consolidated revenue.

Within Pharmacy Solutions, Infusion and Specialty Pharmacy services provide infused, injectable, and oral medication services in the home and clinic, focusing on therapies requiring expert administration and high-touch clinical services. The Company has 149 limited distribution oncology drugs in the market, with an additional 18 expected to launch over the next 12 to 18 months. Home and Community Pharmacy solutions ensure medication accessibility and clinical support for patients outside of retail pharmacies, operating with a localized "white-glove" delivery model within approximately 100 miles of a pharmacy location. This segment achieved a 99.95% generic efficiency rate and saved customers an average of $88 per therapeutic interchange.

The Provider Services segment delivers clinical and supportive care to approximately 16,000 Senior and Specialty populations in home and community settings. Clinical services include home health, hospice, and rehab therapy, while supportive care addresses activities of daily living and social determinants of health. In 2025, the Company delivered approximately 21 million hours of care. Revenue for Provider Services was $1,464.8 million in 2025, contributing 11.3% of total consolidated revenue. The Company is divesting its Community Living business for $835 million , which was previously part of this segment.

For the fiscal year ended December 31, 2025, total revenue increased by $2,838.4 million , or 28.2% , to $12,910.6 million from $10,072.2 million in 2024. Gross profit was $1,517.8 million , resulting in a gross profit margin of 11.7% . Operating income was $295.3 million , representing an operating margin of 2.3% . Net income was $104.8 million , compared to a net loss of $68.9 million in 2024. Diluted EPS was $0.48 , up from a diluted loss per share of $(0.34) in 2024. Adjusted EBITDA increased by $157.4 million , or 34.2% , to $617.6 million . As of December 31, 2025, the Company had $88.4 million in cash and equivalents, total outstanding debt of $2,569.7 million , and net cash provided by operating activities of $490.2 million .

Year-over-year, Pharmacy Solutions segment revenue grew by $2,691.5 million , or 30.7% , to $11,445.8 million in 2025. Provider Services segment revenue grew by $146.9 million , or 11.1% , to $1,464.8 million . The consolidated gross profit margin decreased from 12.6% in 2024 to 11.7% in 2025, primarily due to a mix shift in the Pharmacy Solutions segment with greater relative volume growth in Infusion and Specialty Pharmacy, which have lower margins, and an increase in fulfillment cost per script in Home and Community Pharmacy. Selling, general, and administrative expenses increased by $64.1 million , or 5.5% , but grew less than the revenue growth rate, demonstrating economies of scale.

During 2025, the Company completed three acquisitions within its Provider Services segment for aggregate consideration, net of cash acquired, of approximately $247.0 million . The Company also announced a definitive agreement on January 17, 2025 , to divest its Community Living business for $835 million , which is expected to close in the first fiscal quarter of 2026 . Additionally, the Company repurchased 1,500,000 shares of common stock at an average price of $28.7820 per share in connection with an October 2025 secondary offering.

Business Outlook

The Company anticipates continued growth in its Pharmacy Solutions segment, driven by the increasing demand for health-dependent medications delivered in home and community-based settings. Industry reports suggest that pharmacy solutions tailored for the home environment, such as home infusion and specialty oncology services, will outpace the general pharmacy market growth. The Company's current pharmacy capabilities are expanding to meet this need, with overall pharmacy patient census and prescriptions having grown by 4% over the past year. The Company expects to further increase its market share in these growing segments, particularly in serving home infusion, specialty oncology, behavioral, in-home Seniors, and hospice patients, where it has already observed double-digit growth.

In the Provider Services segment, the Company expects sustained growth, primarily fueled by the aging baby boomer population. Seniors, who constitute a significant majority of the Company's patients, are projected to represent 21% of the U.S. population by 2030, with the population over 85 expected to double by 2040. This demographic shift, coupled with the proven value proposition of home-based health services, is expected to drive increased patient demand and payor support for in-home treatment over higher-cost institutional settings. The Company has expanded its clinical and expert services in home health, rehabilitation, and hospice to address this growing national healthcare need, evidenced by continued census growth in the Provider Services segment.

The Company's strategic divestiture of the Community Living business, expected to close in the first fiscal quarter of 2026 , is anticipated to streamline service offerings, increase strategic focus, enhance operational efficiencies, refine the payor mix, and foster greater clinical integration and business synergy across the Provider Services segment. This divestiture is also projected to augment the Company's expected Revenue and Adjusted EBITDA growth rates and maximize exposure to target growth markets such as home health, rehab, primary care, and hospice. Following the divestiture, the Company's primary focus will be on Seniors and Specialty patients receiving neuro rehab.

Operationally, the Company maintains a strong focus on quality and compliance, which are central to its strategies and mission. The Company's "Quality First" framework, supported by investments in people, training, auditing, signature programs, accreditations, advocacy, and technologies, is expected to continue driving high service levels and patient satisfaction. The Company's home-based primary care, transitional care management programs (including CCRx), and Clinical (Nursing) Hub are key enablers for coordinating pharmacy and provider services, aiming to improve quality and reduce costs within value-based care constructs. These capabilities are expected to further optimize quality outcomes and help reduce unnecessary emergency room visits and hospitalizations across all provider service lines.

The Company plans to continue its strategy of building de novo locations to augment growth and expand its footprint. Since January 1, 2018, the Company has opened 150 de novo offices and clinics, with 7 opened in 2025. These investments are expected to facilitate more integrated care capabilities and serve as a meaningful organic growth driver. The Company's geographic and operational scale provides access to more de novo opportunities, which are typically identified and opened in proximity to existing locations to leverage market knowledge and presence.

In terms of capital allocation, the Company's principal uses of cash and liquidity have historically been for acquisitions, debt service requirements, and financing of working capital. The Company completed three acquisitions in its Provider Services segment in 2025 for approximately $247.0 million . The Company repurchased 1,500,000 shares of common stock in October 2025 at an average price of $28.7820 per share, fully utilizing the authorized repurchase capacity. The Company has no current plans to pay cash dividends on its common stock .

The Company acknowledges potential structural headwinds and execution risks, including the highly competitive U.S. healthcare industry, changes to Medicare and Medicaid rates, cost containment initiatives by third-party payors, and the implementation of alternative payment models. The Company's substantial indebtedness of approximately $2,569.7 million as of December 31, 2025, also presents a risk, requiring a significant portion of cash flows for debt service payments. Changes in drug utilization and pricing, PBM contracts, and pharmaceutical supplier relationships could negatively impact profitability.

Geographic, regulatory, and macro factors also pose constraints. The Company's operations are subject to extensive federal, state, and local laws and regulations, including those related to licensure, certification, billing, and fraud and abuse. Changes in these regulations or their enforcement could lead to increased costs or sanctions. The U.S. federal and state governments continue to consider and enact broad-based legislative and regulatory proposals that could materially impact the healthcare system and the Company's business. The Inflation Reduction Act of 2022, for example, includes provisions that may impact the business, such as reducing the out-of-pocket spending cap for Medicare Part D beneficiaries to $2,000 starting in 2025 and allowing the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs.

Risk Factors

The Company operates in a highly competitive U.S. healthcare industry, facing competition from a broad and diverse set of businesses across both pharmacy and provider services, with some competitors possessing greater financial, technical, and marketing resources, or vertically integrated business models. Significant risks include potential changes to Medicare and Medicaid rates or payment methodologies, which could materially adversely affect revenue and profitability, as the Company derives substantial revenue from these government programs. Cost containment initiatives by third-party payors, including post-payment audits, could lead to reduced payments or recoupments, impacting financial results. The implementation of alternative payment models, such as Accountable Care Organizations (ACOs), and the transition of Medicare and Medicaid beneficiaries to managed care organizations (MCOs) may limit market share and adversely affect revenues if the Company is not included in these programs or cannot secure favorable contracts. Changes in drug utilization, pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement, including the impact of the Inflation Reduction Act of 2022, could negatively affect profitability, with price caps on an initial 10 Part D drugs going into effect on January 1, 2026 . The Company's substantial indebtedness of approximately $2.6 billion as of December 31, 2025, requires a significant portion of cash flows for debt service, limiting funds for other corporate purposes and increasing exposure to interest rate risk on variable rate debt. Operational risks include reliance on continual recruitment and retention of qualified personnel, potential harm from labor relation matters, and delays in collection or non-collection of accounts receivable. The Company is also exposed to substantial malpractice or other similar claims, governmental inquiries, regulatory actions, and whistleblower lawsuits, with insurance potentially not covering all claims. Cybersecurity threats, including data breaches and ransomware attacks, pose significant risks to sensitive business or patient information, potentially leading to liability, litigation, and reputational damage. The pending sale of the Community Living business for $835 million is subject to customary closing conditions, including antitrust approvals, and failure to close could adversely affect the Company's business and financial condition.

Management Priorities

Management's message to shareholders emphasizes the Company's position as a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. They highlight a differentiated approach to care delivery with an integrated and scaled model addressing high-need and high-cost Senior and Specialty patients. Management believes the Company is well-positioned for long-term growth, underpinned by capabilities such as complementary pharmacy and provider services, effective care delivery in home and community settings, and market-leading scale with a focus on operational excellence. Strategic priorities include continuing to expand pharmacy capabilities to meet growing demand, leveraging the aging population to drive growth in provider services, and streamlining service offerings through the divestiture of the Community Living business, which is expected to close in the first fiscal quarter of 2026 for $835 million . Management also stresses a culture of quality and compliance, consistent operational execution, and the ability to build de novo locations and facilitate integrated care, aligning with value-based care reimbursement models.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Who We Are
  2. [2] Item 1, Business — Who We Are
  3. [3] Item 1, Business — Who We Are
  4. [4] Item 1, Business — Who We Are
  5. [5] Item 7, MD&A — Pharmacy Solutions Segment
  6. [6] Item 7, MD&A — Pharmacy Solutions Segment
  7. [7] Item 7, MD&A — Pharmacy Solutions Segment
  8. [8] Item 7, MD&A — Pharmacy Solutions Segment
  9. [9] Item 7, MD&A — Pharmacy Solutions Segment
  10. [10] Item 7, MD&A — Pharmacy Solutions Segment
  11. [11] Item 7, MD&A — Pharmacy Solutions Segment
  12. [12] Item 7, MD&A — Consolidated Results of Operations
  13. [13] Item 7, MD&A — Our Service Offerings
  14. [14] Item 1, Business — Infusion and Specialty Pharmacy
  15. [15] Item 7, MD&A — Infusion and Specialty Pharmacy
  16. [16] Item 1, Business — Home and Community Pharmacy
  17. [17] Item 1, Business — Home and Community Pharmacy
  18. [18] Item 1, Business — Home and Community Pharmacy
  19. [19] Item 7, MD&A — Provider Services
  20. [20] Item 1, Business — Our Platform
  21. [21] Item 7, MD&A — Consolidated Results of Operations
  22. [22] Item 7, MD&A — Our Service Offerings
  23. [23] Item 7, MD&A — Discontinued Operations
  24. [24] Item 7, MD&A — Consolidated Results of Operations
  25. [25] Item 7, MD&A — Consolidated Results of Operations
  26. [26] Item 7, MD&A — Consolidated Results of Operations
  27. [27] Item 7, MD&A — Consolidated Results of Operations
  28. [28] Item 7, MD&A — Consolidated Results of Operations
  29. [29] Item 7, MD&A — Pharmacy Solutions Segment
  30. [30] Item 7, MD&A — Consolidated Results of Operations
  31. [31] Item 7, MD&A — Consolidated Results of Operations
  32. [32] Item 7, MD&A — Consolidated Results of Operations
  33. [33] Item 7, MD&A — Consolidated Results of Operations
  34. [34] Item 7, MD&A — The following table reconciles diluted EPS to Adjusted EPS
  35. [35] Item 7, MD&A — The following table reconciles diluted EPS to Adjusted EPS
  36. [36] Item 7, MD&A — Consolidated Results of Operations
  37. [37] Item 7, MD&A — Consolidated Results of Operations
  38. [38] Item 7, MD&A — Consolidated Results of Operations
  39. [39] Item 7, MD&A — Calculation of Revolving Credit Facility and LC Facility availability
  40. [40] Item 7, MD&A — Debt
  41. [41] Item 7, MD&A — Cash Flow Activity
  42. [42] Item 7, MD&A — Pharmacy Solutions Segment
  43. [43] Item 7, MD&A — Pharmacy Solutions Segment
  44. [44] Item 7, MD&A — Pharmacy Solutions Segment
  45. [45] Item 7, MD&A — Provider Services Segment
  46. [46] Item 7, MD&A — Provider Services Segment
  47. [47] Item 7, MD&A — Provider Services Segment
  48. [48] Item 7, MD&A — Pharmacy Solutions Segment
  49. [49] Item 7, MD&A — Pharmacy Solutions Segment
  50. [50] Item 7, MD&A — Selling, General, and Administrative Expenses
  51. [51] Item 7, MD&A — Selling, General, and Administrative Expenses
  52. [52] Item 7, MD&A — 2025 Key Highlights
  53. [53] Item 7, MD&A — Factors Affecting Results of Operations and Comparability
  54. [54] Item 7, MD&A — 2025 Key Highlights
  55. [55] Item 7, MD&A — Discontinued Operations
  56. [56] Item 7, MD&A — Discontinued Operations
  57. [57] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Issuer Purchases of Equity Securities
  58. [58] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Issuer Purchases of Equity Securities
  59. [59] Item 7, MD&A — Trends and Other Factors Affecting Business
  60. [60] Item 7, MD&A — Trends and Other Factors Affecting Business
  61. [61] Item 7, MD&A — Discontinued Operations
  62. [62] Item 7, MD&A — Trends and Other Factors Affecting Business
  63. [63] Item 7, MD&A — Trends and Other Factors Affecting Business
  64. [64] Item 7, MD&A — 2025 Key Highlights
  65. [65] Item 7, MD&A — Factors Affecting Results of Operations and Comparability
  66. [66] Item 7, MD&A — 2025 Key Highlights
  67. [67] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Issuer Purchases of Equity Securities
  68. [68] Item 5, Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities — Dividends
  69. [69] Item 7, MD&A — Debt
  70. [70] Item 1A, Risk Factors — Changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement may negatively impact our profitability.
  71. [71] Item 1A, Risk Factors — Changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement may negatively impact our profitability.
  72. [72] Item 1A, Risk Factors — Changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement may negatively impact our profitability.
  73. [73] Item 1A, Risk Factors — Our substantial indebtedness of approximately $2.6 billion as of December 31, 2025
  74. [74] Item 7, MD&A — Discontinued Operations
  75. [75] Item 7, MD&A — Discontinued Operations
  76. [76] Item 7, MD&A — Discontinued Operations

Analysis on 5/20/2026